- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Silexion Therapeutics Corp: Silexion Therapeutics Announces Submission of Phase 2/3 Clinical Trial Application to Israel for SIL204 in Locally Advanced Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| Di | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 02.12. | Silexion Therapeutics Corp: Silexion Therapeutics Receives Positive Feedback from German Health Authority on Design of Phase 2/3 Clinical Trial in Pancreatic Cancer | 1 | GlobeNewswire (USA) | ||
| 02.12. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 25.11. | Silexion Therapeutics Corp: Silexion Therapeutics Successfully Completes Toxicology Studies for SIL204, Next-Generation RNA Silencing Therapy, Ahead of Phase 2/3 Clinical Trial in Pancreatic Cancer | 283 | GlobeNewswire (Europe) | Successful completion of two-species toxicology studies confirms no systemic organ toxicity, advancing the Company towards its planned regulatory submissions to Israel and Germany Company remains... ► Artikel lesen | |
| 25.11. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Silexion Therapeutics GAAP EPS of -$2.88 | 2 | Seeking Alpha | ||
| 12.11. | Silexion Therapeutics Corp Announces Drop In Q3 Bottom Line | 3 | RTTNews | ||
| SILEXION THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 12.11. | Silexion Therapeutics Corp: Silexion Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update | 527 | GlobeNewswire (Europe) | Continued advancement toward Phase 2/3 clinical trial initiation, on track for the first half of 2026 New preclinical data demonstrated SIL204's exceptional efficacy across multiple human cancer cell... ► Artikel lesen | |
| 12.11. | Silexion Therapeutics Corp - 8-K, Current Report | - | SEC Filings | ||
| 12.11. | Silexion Therapeutics Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 30.09. | Silexion Therapeutics Corp: Silexion Therapeutics Announces Positive New Human Cell Line Data Confirming Pan-KRAS Activity of SIL204, Demonstrating Up to 99.7% Inhibition and First Evidence in Gastric Cancer | 147 | GlobeNewswire (Europe) | New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence... ► Artikel lesen | |
| 25.09. | Silexion regains Nasdaq compliance, advances cancer therapy program | 1 | Investing.com | ||
| 25.09. | Silexion Therapeutics Corp: Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements | 143 | GlobeNewswire (Europe) | GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference... ► Artikel lesen | |
| 25.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion Therapeutics Shares Surge On Positive Preclinical Pancreatic Cancer Data | 5 | Benzinga.com | ||
| 11.09. | Silexion Therapeutics announces pricing of $6M public offering | 3 | Seeking Alpha | ||
| 11.09. | Silexion Therapeutics Corp - 8-K, Current Report | 1 | SEC Filings | ||
| 11.09. | Silexion-Aktie schießt nach positiven Daten zu Krebsmedikament um 400 % in die Höhe | 5 | Investing.com Deutsch | ||
| 11.09. | Silexion stock soars 400% after positive pancreatic cancer drug data | 2 | Investing.com |
1 2 3 Weiter >>
60 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 78,80 | +1,03 % | Alarm bei Evotec! BioNTech und Vidac Pharma mit Erfolgen beim Kampf gegen Krebs! Analysten raten zum Kauf! | Bei Evotec läuten die Alarmglocken. Ein Großaktionär ist komplett beim deutschen Biotech-Unternehmen ausgestiegen. Dabei notiert das Wertpapier auf dem Niveau von 2016. Einen Meilenstein hat dagegen... ► Artikel lesen | |
| CUREVAC | 3,614 | -1,36 % | BioNTech SE: BioNTech schließt Übernahme von CureVac N.V. samt damit verbundener Nachangebotsfrist ab und stärkt so die einzigartige Position im mRNA-Feld | BioNTech hat das Umtauschangebot zur Übernahme von CureVac abgeschlossenDie Übernahme von CureVac ergänzt BioNTechs Fähigkeiten und unternehmenseigene Technologien im Bereich mRNA-Design, Verabreichungsformulierungen... ► Artikel lesen | |
| AMGEN | 275,00 | -0,63 % | FDA Greenlights Amgen's UPLIZNA For Adults With Generalised Myasthenia Gravis | THOUSAND OAKS (dpa-AFX) - Amgen Inc. (AMGN), Friday, announced that the FDA has expanded UPLIZNA's label to include the treatment of generalized myasthenia gravis in adults who are positive... ► Artikel lesen | |
| NOVAVAX | 5,678 | -0,44 % | Novavax, Inc.: Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights | Total revenue of $70 million in the third quarter of 2025
Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date... ► Artikel lesen | |
| BIOGEN | 143,90 | -0,72 % | Biogen stock rated Outperform by RBC Capital with $210 price target | ||
| MAINZ BIOMED | 1,230 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| VIKING THERAPEUTICS | 29,080 | +0,40 % | Viking Therapeutics, Inc. (VKTX): A Bull Case Theory | ||
| INTELLIA THERAPEUTICS | 7,620 | +0,63 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy | One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures... ► Artikel lesen | |
| TEMPUS AI | 54,00 | +1,89 % | Tempus AI Approaching Profitability Despite GAAP Losses | ||
| BIOCRYST PHARMACEUTICALS | 6,210 | -0,22 % | XFRA BO1: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILBIOCRYST PHARMAC.... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 44,250 | -0,14 % | BioMarin beruft Rashmi Ramchandani zur neuen Chief Accounting Officer | ||
| SAREPTA THERAPEUTICS | 17,175 | -1,07 % | Sarepta-Aktie: Das sind positive Entwicklungen! | Die Aktie von Sarepta Therapeutics hat in den vergangenen Wochen deutlich an Aufmerksamkeit gewonnen, nachdem regulatorische und strategische Entwicklungen neue Perspektiven für das Unternehmen eröffnet... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,710 | +6,32 % | PacBio Announces Third Quarter 2025 Financial Results | MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2025. Third quarter results: Q3 2025Q3 2024Revenue$38.4... ► Artikel lesen | |
| EXELIXIS | 35,600 | -1,98 % | Citizens reiterates Market Outperform rating on Exelixis stock at $50 | ||
| CARDIOL THERAPEUTICS | 0,845 | -1,52 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
17.12.2025 / 14:38 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen |
SILEXION THERAPEUTICS CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,375 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SILEXION THERAPEUTICS CORP finden Sie auf Wallstreet Online.